Please assess the completion status of the following clinical trial:

Trial Title: Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age be \< 30 years of age at the time of initial diagnosis.~* Patients must have a diagnosis of neuroblastoma (ICD-O morphology 9500/3) verified by histology and/or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites. Patients with the following disease stages at diagnosis are eligible, if they meet the other specified criteria. The revised International Neuroblastoma Staging System (INSS) will be used to stage all patients 58. (See 14.3 for risk assignment).~* Patients with newly diagnosed neuroblastoma and age \> 547 days with the following:~  * INSS Stage 4 neuroblastoma regardless of biologic factors~ * INSS Stage 2A/2B with MYCN amplification (\> 10)~ * INSS Stage 3 with MYCN amplification (\> 10) OR Unfavorable histology~* Patients with newly diagnosed neuroblastoma and age \< 365 days with the following:~  \* INSS Stage 3, 4, OR 4S neuroblastoma AND MYCN amplification (\> 10).~* Patients with newly diagnosed Neuroblastoma and age 365 - \<547 days with the following:~  * INSS Stage 3 with MYCN amplification (\> 10)~ * INSS Stage 4 with MYCN amplification (\> 10) OR with deoxyribonucleic acid (DNA) Index (ploidy) = 1 OR with Unfavorable histology~* Patients \> 365 days with INSS Stage 1, 2, and 4S who have progressed to Stage 4.~* Newly Diagnosed patients should be entered on this study within 4 weeks of diagnosis, or after receiving only one cycle of intermediate dose chemotherapy for patients initially treated on/according to the low or intermediate risk Children's Oncology Group (COG) neuroblastoma studies, or within 4 weeks of progression to Stage 4 for INSS Stage 1, 2, 4S.~* Patients treated with alternative induction regimens and/or consolidation regimens (AutoSCT) who were not enrolled at diagnosis but who achieve a complete response (CR), very good partial response (VGPR), partial response (PR), or minimal response (MR) and meet all other criteria will be eligible for either the consolidation MAT/AutoSCT and NAT/AlloSCT immunotherapy or NAT/AlloSCT, which ever is clinically appropriate after discussion with the Principal Investigators.~* Liver Function: alanine aminotransferase (ALT) and bilirubin \< 3x normal~* Cardiac Function: Shortening fraction \> 27%, or ejection fraction \> 47%, no clinical congestive heart failure.~* Renal Function: Creatinine clearance and/or glomerular filtration rate (GFR) \> 60 ml/min/1.73m2.~* Hematologic Function: Patients must have adequate hematopoietic function (absolute neutrophil count (ANC) \> 1000/mm3 and platelets \> 100,000/mm3) unless inadequate hematopoiesis documented to be due to bone marrow involvement with tumor (\> 10% tumor infiltration).~Exclusion Criteria:~* Patients who are pregnant. Patients of childbearing potential must practice an effective method of birth control while participating on this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Arm A - Related Donor (Type: EXPERIMENTAL): Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
- Arm B - Cord Blood Donor (Type: EXPERIMENTAL): Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues